News and Breakthroughs
Find the latest news and discoveries, as well highlights from Lurie Cancer Center’s programs and events through the links below. To learn more about our accomplishments and the people who make them possible, visit the article archive for older news and read our 2020 Year in Review.
Visit our gallery to view a wide range of photos and videos for oncology professionals, cancer patients and families, cancer survivors, caregivers and community members.
A new way to significantly increase the potency of almost any vaccine has been developed by Northwestern scientists.
Northwestern Medicine investigators have discovered that specific calcium channels help regulate sex differences in the functioning of immune cells for neuroinflammation and overall neuropathic pain.
Scientists have identified a new cell type implicated in the development of medulloblastoma, according to a study published in Nature.
Targeting cellular post-transcription mechanisms in the CD73 ectoenzyme may promote anti-tumor immunity and slow cancer progression in triple-negative breast cancer, according to a recent Northwestern Medicine study.
The National Comprehensive Cancer Network’s new Diversity, Equity, & Inclusion (DEI) Directors Forum is working to improve diversity of clinical staff representation across the nation’s leading academic cancer centers. June McKoy, MD, MPH, JD, MBA, assistant director of Diversity, Equity, and Inclusion at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, has been selected to join the forum.
High doses of vitamin D alleviated symptoms for patients with toxic erythema of chemotherapy significantly faster than current treatments, according to a recent study.
We are pleased to announce that Sofia Garcia, PhD, has been named director of the Cancer Survivorship Institute of the Lurie Cancer Center, effective January 1, 2023.
On Monday, January 16, we honor the life and legacy of Dr. Martin Luther King Jr. The Northwestern community will celebrate Dr. King with an expanded special commemoration to inspire reflection and keep the dream alive.
Patients with relapsed or refractory hairy cell leukemia who were treated with vemurafenib experienced excellent response and relapse-free survival, according to a recent clinical trial published in Blood.
Northwestern Medicine investigators have revealed new insights into how cell type switches facilitate tumor growth and treatment resistance in small cell lung cancer, according to findings published in Science Advances.
The Robert H. Lurie Comprehensive Cancer Center of Northwestern University is pleased to announce that Mario Shields, PhD, a research assistant professor of Medicine in the Division of Hematology and Oncology, has received the first Diversity Scholars Award.
The Lurie Cancer Center is pleased to announce IDP Research Innovation Challenge Award recipients for 2023.
Patient-reported outcomes in relapsed or refractory large B-cell lymphoma revealed that receiving CAR T-cell immunotherapy was associated with higher quality of life, according to a recent study.
A Northwestern Medicine study has discovered that elevated PALI1 in advanced prostate tumors mediates crosstalk between two primary epigenetic silencing mechanisms, suggesting that dual epigenetic inhibition may be an effective therapeutic strategy.
Investigators have developed a novel personalized T-cell therapy approach that may identify specific targets unique to a patient’s cancer cells more effectively than current treatments, according to findings published in Nature.
Northwestern Medicine scientists have identified a new therapeutic target against tumor cells and developed a compound which slows tumor growth and bolsters immune response.
Bin Zhang, MD, PhD, a recognized expert in cancer immunology and immunotherapy research, has been named Co-Leader of the Tumor Environment and Metastasis Program (TEAM) at the Lurie Cancer Center, effective February, 2023.
Lurie Cancer Center investigators have received one of four inaugural Class of 2022 TACTICAL (Therapy ACceleration To Intercept CAncer Lethality) Awards from the Prostate Cancer Foundation (PCF). PCF’s $30 million program will support cross-disciplinary pioneering research toward the goal of developing 21st Century therapies for the most life-threatening form of prostate cancer.
Understanding how genes function is a vital part of understanding how to better treat cancer. Research led by Mazhar Adli, PhD, is grounded in the development of a systematic approach to identify the function of each gene in the human body. His team aims to discover novel therapeutic drug combinations to prevent cancer development and chemotherapy resistance.
Physicians and scientists from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Northwestern Medicine will present and discuss exciting new research and important clinical findings at the American Society of Hematology (ASH) Annual Meeting, December 10-13 in New Orleans. With more than 18,000 members from nearly 100 countries, ASH is the world’s largest professional society serving both clinicians and scientists around the world who are working to conquer blood diseases.
Physicians and scientists from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Northwestern Medicine will lead and participate in a wide range of sessions at the 45th annual San Antonio Breast Cancer Symposium, December 6 -10, 2022.
David VanderWeele, MD, PhD, an expert in the field of genome-based therapies and genitourinary cancer, has been appointed director of the Lurie Cancer Center OncoSET Precision Oncology Program, and Erica Vormittag-Nocito, MD, a specialist in molecular genetic pathology, has been named director of Cancer Molecular Diagnostics at the Lurie Cancer Center.
Investigators have identified previously unknown sets of epigenetic changes in pediatric brain tumors, which could serve as novel therapeutic targets and provide alternative treatment options.
Synthetic biology is a robust interdisciplinary field that uses tools and concepts from engineering, physics and computer science to build new biological systems. At Feinberg, scientists are pursuing synthetic biology research to address the health challenges and diseases that humans face.
Lurie Cancer Center is pleased to announce the recipients of its 2022 Translational Bridge Program awards, selected to foster collaboration and mentorship with the goal of translating basic science research into novel clinical approaches.
Ten members of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University are among the “world’s most influential scientific minds,” according to the prestigious Highly Cited Researchers (HCR) list published by the Institute for Scientific Information at Clarivate. These investigators have “demonstrated significant and broad influence in their chosen fields of research over the last decade, and their highly cited papers rank in the top 1% by citations for their field and publication year.
The Hippocratic Cancer Research Foundation (HCRF) hosted The Wings to Cure Gala on Saturday, November 12 to benefit cutting-edge translational research at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
Investigators have discovered novel genetic factors that contribute to the risk of Parkinson’s disease, according to a recent Northwestern Medicine study.
Physicians and scientists from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Northwestern Medicine will present and discuss multidisciplinary brain tumor research at the 2022 Society for Neuro-Oncology Annual Meeting (SNO), focused on the bridge between neuro-oncology research and brain cancer care.
See more news in the article archive.